Home > Back to Publisher > Report Information

Biomarker and Diagnostic Opportunities in Clinical Research for Neurological Diseases

Decision Resources
October 13, 2009
32 Pages - SKU: DECR2497069

Abstract Table of Contents Related Reports

Introduction

Biomarkers and imaging tools are enabling technologies in today's clinical research efforts for neurological diseases. Whether to improve upon existing methods for monitoring disease progression or to discover validated measures to detect diseases earlier than before, nearly every neurology trial is relying on biomarkers and/or has an imaging component. Although some biomarkers and imaging tools are better than others, companies in this market that are aiming to unveil a truly unique or even a significantly improved therapy must incorporate biomarkers in their R&D strategies-it would be foolish not to.

Get the Answers You Need to Shape Your Strategy

The uses of biomarkers in neurology are varied-drug discovery, monitoring disease progression/drug action, and diagnostic development-and can depend on the indication. In what ways are biomarkers being explored in Parkinson's disease compared with Alzheimer's disease? How has the use of biomarkers aligned with an outcome measure for a study in ALS?
Clearly defined biomarkers in the neurology therapeutic area are missing. Are we close to discovering appropriate biomarkers for use in diagnostic tests to detect diseases early enough to truly change the therapeutic landscape in neurology?
Imaging modalities are used frequently in neurological drug and diagnostic research. How many industry- sponsored active studies are employing imaging tools as their biomarker intervention? Which indication(s) relies on imaging the most?

Scope

High-interest neurological diseases: Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), multiple sclerosis (MS), and Parkinson's disease (PD).
Analysis of 117 biomarker-based clinical trials as of September 2009: Study type, phase in development, indication.
A look at 75 biomarker/diagnostics-based deals across six years: Company type (large-cap, midcap, small-cap), deal type, and indication-specific.

Please note, the PDF e-mail from publisher version of this report is for a global site license.

Executive Summary: Strategic Considerations; Stakeholder Implications
Introduction
Diagnosing Neurological Diseases
Diagnostic Imaging Applications
Biomarkers in Clinical Trials
Indication-Specific Biomarkers of Interest: Alzheimer’s Disease and Mild Cognitive Impairment; Multiple Sclerosis; Parkinson’s Disease; Amyotrophic Lateral Sclerosis; Huntington’s Disease
Biomarker and Diagnostic Neurology Deals: Indication-Specific Deals; Company-Specific Deals
Outlook
Sidebar: Commonly Used Imaging Technologies in Clinical Neurology
Expert Commentary: “Value of Licensing Biomarkers of Alzheimer’s Disease.”; Q&A with Rainer Voegeli, Ph.D., Commercial Director at Proteome Sciences
Tables: 1. Descriptions of Select Neurological Diseases; 2. Top Five Currently Recruiting Clinical Trials in Neurology, Largest Enrollment; 3. Diagnostic Tests for Multiple Sclerosis; 4. Inheritance Patterns of Huntington’s Disease; 5. Biomarker and Diagnostic Neurology Deals in the First Half of 2009; 6. Biomarker and Diagnostic Deals Involving Large-Cap Healthcare Companies, 2004- First Half 2009
Figures: 1. Biomarker-Based, Closed-Enrollment, Completed Neurology Clinical Trials by Phase and Indication, September 2009; 2. Biomarker-Based, Closed-Enrollment, Active Neurology Clinical Trials by Phase and Indication, September 2009; 3. Biomarker-Based, Open-Enrollment, Currently Recruiting Neurology Clinical Trials by Phase and Indication, September 2009; 4. Biomarker-Based, Open-Enrollment, Not Currently Recruiting Neurology Clinical Trials by Phase and Indication, September 2009; 5. Amyloid Plaques and Neurofibrillary Tangles in Alzheimer’s Disease; 6. Rate of Dopaminergic Neuron Loss over the Course of Parkinson’s Disease; 7. Number of Neurology Biomarker and Diagnostic Deals, 2004-First Half 2009; 8. Neurology Deals: Biomarkers vs. Diagnostics, 2004-First Half 2009; 9. Number of Neurology Biomarker and Diagnostic Deals, by Deal Focus, 2004-First Half 2009; 10. Number of Neurology Biomarker and Diagnostic Deals, by Indication, 2004-First Half 2009; 11. Companies with the Most Neurology Biomarker and Diagnostic Deals, 2004-First Half of 2009; 12. Number of Neurology Biomarker and Diagnostic Deals, by Company Type, 2004-First Half 2009

Biomarker and Diagnostic Opportunities in Clinical Research for Neurological Diseases

Share this report

Other tasks

Research Assistance

Related Markets

CNS/Neurology Reports

Free Alert Me service